Trial Profile

Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Nadroparin calcium (Primary) ; Tinzaparin sodium (Primary)
Indications Embolism and thrombosis; Venous thromboembolism
Focus Therapeutic Use
Acronyms COVI-DOSE

17 Dec 2021 Status changed from recruiting to completed.
10 Nov 2020 Planned End Date changed from 1 Oct 2020 to 1 Nov 2021.
10 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Nov 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com